GLAUKOS CORP.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 907
- Market Cap
- $7.4B
- Website
- http://www.glaukos.com
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
Phase 4
Recruiting
- Conditions
- Glaucoma, Open-angleOcular Hypertension (OHT)Phacoemulsification Cataract Surgery
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 132
- Registration Number
- NCT06848946
- Locations
- 🇺🇸
Glaukos Investigator Site, Kenosha, Wisconsin, United States
Performance of the Travoprost Intraocular Implant
Phase 2
Completed
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 210
- Registration Number
- NCT06582732
- Locations
- 🇦🇲
Glaukos Clinical Study Site, Yerevan, Armenia
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
Phase 2
Recruiting
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT06152861
- Locations
- 🇺🇸
Glaukos Clinical Study Site, Newport Beach, California, United States
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
Phase 3
Recruiting
- Conditions
- Glaucoma, Open-Angle
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT06066645
- Locations
- 🇺🇸
Glaukos Clinical Study Site, Colorado Springs, Colorado, United States
Travoprost Intraocular Implant in Conjunction With Cataract Surgery
Phase 3
Active, not recruiting
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- Drug: iDose TR
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT06061718
- Locations
- 🇦🇲
Glaukos Clinical Study Site, Yerevan, Armenia
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Not Applicable
Recruiting
- Conditions
- Glaucoma
- Interventions
- Device: iStent Infinite
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 245
- Registration Number
- NCT06057051
- Locations
- 🇺🇸
Glaukos Investigator Site, Cincinnati, Ohio, United States
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
Phase 1
Recruiting
- Conditions
- Progressive Keratoconus
- Interventions
- Combination Product: NXL Energy 3Combination Product: NXL Energy 1Combination Product: NXL Energy 2Combination Product: Sham Treatment
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT05314738
- Locations
- 🇺🇸
Glaukos Investigative Site, Westerville, Ohio, United States
Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor
Not Applicable
Active, not recruiting
- Conditions
- GlaucomaGlaucoma, Open-Angle
- Interventions
- Device: iStent InfiniteDevice: Competitor Device
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 179
- Registration Number
- NCT05127551
- Locations
- 🇨🇦
Glaukos Investigator Sites, Montréal, Qubec, Canada
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia
Phase 2
Completed
- Conditions
- Presbyopia
- Interventions
- Drug: Placebo Ophthalmic Topical Cream
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 123
- Registration Number
- NCT05124275
- Locations
- 🇺🇸
Glaukos Investigator, San Antonio, Texas, United States
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease
Phase 2
Completed
- Conditions
- Kerato Conjunctivitis SiccaDry Eye Disease
- Interventions
- Drug: Placebo Ophthalmic Topical Cream
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 226
- Registration Number
- NCT05119920
- Locations
- 🇺🇸
Glaukos Investigator, Lynchburg, Virginia, United States